Resources from the same session
502MO - Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma: A real-life cohort analysis from Veneto Institute of Oncology, Padua (Italy)
Presenter: Giulia Cerretti
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
503MO - Real-world clinical and genomic characterization of gliomas: Predictive and prognostic insights
Presenter: Oriol Mirallas
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
504MO - Validation of a spectroscopic liquid biopsy for the earlier detection of brain cancer
Presenter: James Cameron
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
505MO - A phase 0/Ib study of AZD1390 plus radiotherapy in recurrent glioblastoma patients
Presenter: Nader Sanai
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
506MO - A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients (pts) with recurrent meningioma
Presenter: Wenbin Li
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 505MO and 506MO
Presenter: Andreas Hottinger
Session: Mini oral session: CNS tumours
Resources:
Slides
Webcast
507MO - REGOMA-OS: A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients
Presenter: Giuseppe Lombardi
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
508MO - Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial
Presenter: Julian Philipp Layer
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 507MO and 508MO
Presenter: Emeline Tabouret
Session: Mini oral session: CNS tumours
Resources:
Slides
Webcast